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Abstract
Controlling the balance of pro-inflammatory M1 versus anti-inflammatory M2 macrophages may have paramount therapeutic 
benefit in cardiovascular diseases, infections, cancer and chronic inflammation. The targeted depletion of different macrophage 
populations provides a therapeutic option to regulate macrophage-mediated functions. Macrophages are highly sensitive to 
necroptosis, a newly described regulated cell death mediated by receptor-interacting serine/threonine-protein kinase 1 (RIPK1), 
RIPK3 and mixed lineage kinase domain like pseudokinase. Antagonists of inhibitors of apoptosis proteins (SMAC mimetics) 
block RIPK1 ubiquitination, while TGF-activated kinase 1 (TAK1) inhibitors prevent the phosphorylation of RIPK1, result-
ing in increased necroptosis. We compared the sensitivity of monocyte-derived human M1 and M2 cells to various apoptotic 
and necroptotic signals. The two cell types were equally sensitive to all investigated stimuli, but TAK1 inhibitor induced more 
intense necroptosis in M2 cells. Consequently, the treatment of co-cultured M1 and M2 cells with TAK1 inhibitor shifted the 
balance of the two populations toward M1 dominance. Blockage of either Aurora Kinase A or glycogen synthase kinase 3β, 
two newly described necroptosis inhibitors, increased the sensitivity of M1 cells to TAK1-inhibitor-induced cell death. Finally, 
we demonstrated that in vitro differentiated tumor-associated macrophages (TAM-like cells) were as highly sensitive to TAK1 
inhibitor-induced necroptosis as M2 cells. Our results indicate that at least two different necroptotic pathways operate in mac-
rophages and the targeted elimination of different macrophage populations by TAK1 inhibitor or SMAC mimetic may provide 
a therapeutic option to regulate the balance of inflammatory/anti-inflammatory macrophage functions.
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Introduction
Macrophages with highly polarized functions coexist in tis-
sues throughout the body to ensure the modulation of immune 
responses. Traditionally, macrophages can be subdivided into 
classically activated M1 and alternatively activated M2 phe-
notypes. M1 cells provide the first line of immune defense and 
activate both innate and adaptive immunity, while M2 mac-
rophages are responsible for the regulation of tissue regenera-
tion, are involved in the clearance of apoptotic bodies and con-
tribute to the immune suppression [1]. Controlling the balance 
of pro-inflammatory versus anti-inflammatory macrophages 
may have paramount therapeutic benefit in all the world’s 
leading causes of death, such as in cardiovascular diseases 
[2, 3], infections [4], cancers [5, 6], chronic inflammation [7], 
diabetes [8] or autoimmune reactions [9].
The success of immunotherapy highlights the effective-
ness of the immune system in tumor eradication. Tumors 
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still develop in spite of the immune attack, because tumors 
are surrounded by immunosuppressive cells and can escape 
from immune surveillance by hampering the onset of an effec-
tive anti-tumor immune response [10]. The tumor microen-
vironment (TME) consists of various immune cells, where 
macrophages form one of the most abundant cell popula-
tions. Solid tumors manipulate macrophage recruitment 
and regulate macrophage differentiation. Reprogrammed 
tumor-associated macrophages (TAM) supports tumor for-
mation through upregulation of angiogenesis, growth factor 
production or immunosuppression, and these cells also pro-
mote metastasis and increase drug resistance [5, 6], Unlike 
monocytes, macrophages have a long life span of months to 
years [11]. Accordingly, macrophages are relatively resistant 
to most apoptotic stimuli, but are highly sensitive to two newly 
described inflammatory forms of regulated cell death, necrop-
tosis [12, 13] and pyroptosis [14]. Necroptosis is a regulated 
event rather than an accidental cell death process in which 
the most critical contributors are receptor-interacting protein 
1 (RIPK1) [15], RIPK3 [16] and mixed lineage kinase domain 
like pseudokinase (MLKL) [17]. Necroptosis is known to play 
an important role in the pathogenesis of many diseases, such 
as neurodegenerative or inflammatory disorders, gastrointes-
tinal, cardiovascular and pulmonary diseases [18]. The critical 
receptors of macrophages such as death, pattern recognition, 
DNA binding, cytokine and adhesion receptors all have been 
identified as potential inducers of necroptosis [19]. Necroptosis 
can be activated when apoptosis is blocked and pro-necroptotic 
proteins are released from caspase-8-mediated inhibition [15]. 
Active caspase-8 blocks the necroptotic mode [15] of action 
preferentially through the cleavage of RIPK1 [20], RIPK3 [21] 
and the cylindromatosis (CYLD) protein, which mediates deu-
biqutination of RIPK1 [22]. The ubiquitination of RIPK1 by 
inhibitors of apoptosis proteins (cIAPs) initiates cell survival 
[23]. The created ubiquitin network allows the activation of 
TGF-activated kinase 1 (TAK1), which mediates survival sig-
nals by (1) activating the NFκB and MAPK signaling pathways 
and thereby increasing the expression of several prosurvival 
molecules [24, 25], (2) preventing the interaction between 
RIPK1 and cell death-related molecules [26], (3) regulating 
RIPK1 phosphorylation directly [27] or indirectly by activat-
ing I kappa B kinases (IIKKα/IKKβ) [28] or mitogen-activated 
protein kinase-activated protein kinase 2 (p38MAPK/MK2) 
[29]. In addition to TAK1- and cIAP-mediated downregula-
tion, more than 70 molecules play a role in the regulation of 
necroptosis [18], among them Aurora kinase A (AURKA), 
which interacts directly with RIPK1 and RIPK3 in nontreated 
cells to reduce unwanted necroptosis [30]. Its downstream tar-
get glycogen synthase kinase 3β (GSK3β) regulates the for-
mation of the necrosome and suppresses necroptosis [30]. In 
the absence of ubiquitylation and/or phosphorylation, RIPK1 
transduces cell death signals, and when apoptotic pathways 
are blocked, necroptosis is activated. Thus, necroptosis is most 
frequently induced in in vitro experimental systems by uti-
lizing pan caspase inhibitors in combination either with IAP 
antagonists, termed SMAC mimetics (SM) to block RIPK1 
ubiquitination [12], or with TAK1 inhibitors to prevent the 
phosphorylation of RIPK1 [13]. Necroptotic cell death of mac-
rophages has already been shown following treatment with SM 
[31] or TAK1 inhibitors [14].
Many clinical trials aim to modify the M1/M2 ratio, but 
currently, the targeted depletion of a unique macrophage 
subtype by specific cell death signals is not a therapeutic 
option. We aimed to identify circumstances in which M2 
cells or TAMs are susceptible to cell death signals, but M1 
cells remain resistant. We found that M2 macrophages were 
highly sensitive, while M1 macrophages were unaffected 
by TAK1 inhibitor-generated necroptosis. The resistant M1 
macrophages harness AURKA-mediated inhibition in the 
downregulation of cell death. In contrary to TAK1 inhibitor, 
SM treatment results in necroptosis in both macrophage pop-
ulations, highlighting that at least two different necroptotic 
pathways operate in macrophages. TAK1 inhibitor-induced 
necroptosis pushes the ratio of M1/M2 macrophages toward 
an inflammatory phenotype, which rationalizes the activation 
of necroptosis for therapeutic intervention in any disease 
where M1 functions are preferred.
Materials and methods
Antibodies and reagents
The following commercial antibodies and reagents were 
used in this study: Z-VAD, AURKA inhibitor CCT137690, 
MAPK inhibitors SB203508-p38, U0126-ERK, NFκB inhib-
itor-TPCA1-IKK were purchased from ApexBio, GSK3ß 
inhibitor AR-A014418 was from Selleck Chemicals, and 
SP600125-JNK was from Santa Cruz. TNF alpha was pur-
chased from PeproTech. 5Z-7-oxozeaenol (5Z-7) and RIPK3 
inhibitor (GSKʹ872) were from Sigma-Aldrich. Necrostatin-1 
was from Abcam, and TNF-R1:Fc fusion protein was from 
Adipogen. Lipopolysaccharide (LPS) was from InvivoGen, 
and Birinapant was from LC Laboratories. The flow cytom-
etry antibodies were purchased from the following compa-
nies: CD209-PE (DC-SIGN, BioLegend), CD206-Pe-CyTM5 
(BD Pharmingen) and CD80-FITC (SONY Biotechnology), 
CD14-PE (BioLegend), HLA-DR-PercP (BD Pharmingen), 
PD-1/CD279-PercP (BioLegend), CD163-PE (Biosciences).
Generation of monocyte‑derived M1, M2 
macrophages and TAM‑like cells
Heparinized leukocyte-enriched buffy coats were obtained 
from healthy blood donors, and peripheral blood mononu-
clear cells (PBMCs) were separated from buffy coats by 
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Ficoll-Paque Plus (Biosciences) gradient centrifugation. 
Monocytes were purified from PBMCs by positive selec-
tion using immunomagnetic cell separation and anti-CD14-
conjugated microbeads (Miltenyi Biotec), according to the 
manufacturer’s instructions. After separation on a Vari-
oMACS magnet, 96–99% of the cells were shown to be 
 CD14+ monocytes.
Isolated monocytes were cultured for 5 days in 6-well tis-
sue culture plates at a density of 2.0 × 106 cells/ml in Gibco’s 
serum-free AIM-V medium (Thermo Fischer Scientific) sup-
plemented with 50 ng/ml M-CSF (PeproTech). In order to 
acquire the M1 and M2 types, cells were stimulated on the 
fifth day of differentiation for 24 h with lipopolysaccharide 
(50 ng/ml ultrapure LPS, InvivoGen), IFNγ (20 ng/ml, Pep-
roTech) to M1 and IL-4 (20 ng/ml, PeproTech), IL-10 (20 ng/
ml, PeproTech) and TGFß (20 ng/ml, PeproTech) to M2 phe-
notype. For the differentiation of TAM-like cells, isolated 
monocytes were cultured for 5 days in 6-well tissue culture 
plates at a density of 2.0 × 106 cells/ml in Thp-1 supernatant 
supplemented with IL-4 (20 ng/ml), IL-10 (20 ng/ml) and 
TGFß (20 ng/ml). On the fifth day, TAM-like cells were 
treated again with Thp-1 supernatant for 24 h.
Production of THP‑1 supernatant
To generate THP-1 supernatant, cells were cultured at a 
density of 2 × 105 cells/ml in Gibco’s serum-free AIM-V 
medium (Thermo Fischer Scientific) for 2 days and the 
supernatant was collected at 1500 rpm for 5 min.
Measurement of cytokine concentration
The supernatants of M1 and M2 macrophages were har-
vested on the sixth day of differentiation, and the concen-
trations of IL-12 and IL-10 cytokines were measured using 
OptEIA kits (BD Biosciences) following the manufacturer’s 
instructions.
Flow cytometry
Cell death was induced by TAK1 inhibitor (5Z-7-oxoze-
aenol 1 µM), IAP antagonist (Birinapant 0.5 µM) LPS 
(100 ng/ml), TNF alpha (60 ng/ml), caspase inhibitor 
(Z-VAD 50 µM), RIP1K inhibitor, Necrostatin-1 38.5 μM), 
RIPK3 inhibitor (GSKʹ872 7.5 μM), AURKA inhibitor 
(CCT137690 1.25 μM), GSK3β inhibitor (AR-A014418 
10 μM) and MAPK (SP600125-JNK 1 µM; SB203580-p38 
1 µM; U0126-Erk 1 µM) and NFκB inhibitors (TPCA1-
IKK 1 µM) on M1, M2, TAM and M1-M2 co-cultured 
macrophages.
Total cell death was quantified based on the loss of 
membrane integrity and the uptake of propidium iodide 
(PI, Sigma-Aldrich). Cells were stained with PI (10 µg/ml) 
before analysis by flow cytometry. Cell death was measured 
by flow cytometry using FACS Calibur (BD Biosciences), 
and data were analyzed by FlowJo software (Tree Star, Ash-
land, OR, USA).
Western blotting
Protein extraction was performed by lysing the cells in 2 × 
Laemmli sample buffer. Proteins were separated by SDS gel 
electrophoresis using 10% polyacrylamide gels and trans-
ferred onto nitrocellulose membranes ER (Bio-Rad Labo-
ratories). Nonspecific binding was blocked by TBS-Tween 
with 5% nonfat dry milk. Transfer membranes were immu-
noblotted with the indicated antibodies: RIPK1 (BD Bio-
sciences), RIPK3 (Cell Signaling), MLKL (Sigma-Aldrich), 
pMLKL (Cell Signaling), TAK1 (Cell Signaling), GSK3ß 
(Cell Signaling), Aurora A (Cell Signaling), p38 (Thermo 
Fischer Scientific), pErk (Thermo Fischer Scientific), pJNK 
(Thermo Fischer Scientific), pIκß (R&D Systems) and 
β-actin (Sigma-Aldrich) all diluted 1:1000. Anti-rabbit (GE 
Healthcare), anti-mouse (GE Healthcare) or anti-rat (Sigma-
Aldrich) antibodies conjugated to horseradish peroxidase 
were used as the secondary antibodies.
Co‑cultures of M1–M2 cells
To test the functional importance of differences in cell death 
intensity between M1 and M2 cells, a macrophage co-culture 
was created.
An equal number of M1 and M2 macrophages, 4 × 105 
cells/0.5 ml, were co-cultured for 4 h in 24-well tissue cul-
ture plates. Mixture of M1 and M2 cells was treated with 
necroptotic stimuli. The percentage of surviving mac-
rophages was labeled with anti-CD209-PE and anti-CD80-
FITC antibodies in 24 h.
To distinguish between M1 and M2 cell death, M2 mac-
rophages were stained using CellTracker™ Green CMFDA 
Dye (Thermo Fischer Scientific). M2 cells were loaded with 
10 ng/ml CellTracker™ Green CMFDA Dye at 37 °C for 
30 min. After intense washing,  4x105 cells in 0.5 ml volume 
were co-cultured with unlabeled M1, in the same concentra-
tion in 24-well tissue culture plates. M1 and M2 co-cultures 
were treated with necroptotic stimuli, and the cell death of 
the different populations was determined after 24 h by PI 
staining.
Statistical analysis
Two-way ANOVA or one-way ANOVA followed by Sidak’s 
multiple-comparison test was used for multiple comparisons. 
Results are expressed as mean ± SD. In the case of IL10 and 
IL-12 production, significance was calculated by Student’s 
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t test. The results are expressed as mean +SD. All analyses 
were performed by using GraphPad Prism software, ver-
sion 6.0. Differences were considered to be statistically sig-
nificant at P < 0.05. Significance is indicated by *P < 0.05; 
**P < 0.01; ***P < 0.005.
Results
M2 macrophages, but not M1 cells are sensitive 
to TAK1 inhibitor‑induced necroptosis
Controlling the balance of pro-inflammatory versus anti-
inflammatory macrophages may provide immediate thera-
peutic benefit. As a new concept for therapeutic inter-
vention, we compared the sensitivity of human M1 and 
M2 macrophages to various cell death stimuli. For this, 
blood-derived CD14+ monocytes were separated and 
differentiated, in accordance with previous studies, in the 
presence of M-CSF for five days to M0 macrophages and 
then polarized toward the M1 and M2 cells by stimulation 
for 24 h with LPS/IFNγ or IL-4/TGFβ, respectively [32]. To 
confirm the polarization of subtypes, we analyzed cell sur-
face marker expression on the differentiated macrophages. 
We detected the induction of CD80 on M1 cells, and higher 
expression level of prototypical M2 markers CD206 and 
CD209 on M2 cells (Fig. 1a). We also checked the function-
ality of the two cell populations by measuring the production 
of M1- and M2-related cytokines. According to widely used 
protocols, M1 cells released significantly higher amounts 
of IL-12 than the M2 population, but IL-10 production was 
more relevant in M2 macrophages (Fig. 1b, c) [33].
To check the susceptibility to cell death stimuli of polar-
ized M1 and M2 macrophages, we treated these cell types 
with various apoptotic and necroptotic activators. We used 
LPS, TNF, SMAC mimetic (birinapant), TAK1 inhibitor 
co
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Fig. 1  In vitro differentiation of M1 and M2 macrophages. a Human 
monocyte-derived macrophages were differentiated to M1 and M2 
phenotype in the presence of LPS (50 ng/ml) and IFNγ (20 ng/ml) or 
IL-4 (20 ng/ml), IL-10 (20 ng/ml) and TGFß (20 ng/ml), respectively. 
The cell surface expressions of CD80, CD206 and CD209 were 
measured on the two cell types by flow cytometry. Representative 
images of five independent experiments are shown. b, c The IL-12 
and IL-10 production was measured by ELISA. The figure shows the 
average of three independent experiments
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Fig. 2  TAK1 inhibitor induces necroptosis on M2, but not on M1 
cells. a The in  vitro differentiated human M1 and M2 cells were 
stimulated with 100  ng/ml LPS, 60  ng/ml TNF, 0.5  μM birinapant 
and 1  μM 5Z-7-oxozeaenol with and without 50  μM Z-VAD. b, c 
Cells were stimulated with the indicated dose of or 5Z-7-oxoze-
aenol or birinapant in the presence or absence of 50 μM Z-VAD. d 
Cells were pretreated with 7.5  μM GSKʹ872 RIPK3 inhibitor and 
38.5 μM Necrostatin-1 for 1 h, after which 0.5 μM birinapant or 1 μM 
5Z-7-oxozeaenol together with 50 μM Z-VAD was added. After 24 h, 
cell death was determined by PI staining. Figures show the mean plus 
SD of at least three independent experiments. e MLKL phospho-
rylation (S358) was detected by WB following 0.5 μM birinapant or 
1 μM 5Z-7-oxozeaenol treatment for the indicated times. A represent-
ative image of three independent experiments
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(5Z-7-oxozeaenol; 5Z-7) and the combinations of these 
treatments as apoptotic triggers. In the presence of a cas-
pase inhibitor (Z-VAD), all these stimulants are well-known 
activators of necroptosis in macrophages [14, 31]. All the 
investigated stimuli induced cell death at the same level in 
both cell populations, but TAK1 inhibitor-induced necrop-
tosis was significantly higher in M2 cells (Fig. 2a).
To confirm this result, we studied the dose dependence 
of birinapant- and 5Z-7-mediated cell death. 5Z-7-induced 
cell death was more intense in M2 cells than in M1 mac-
rophages under caspase-compromised conditions at all 
investigated doses (Fig. 2b). Under the same experimental 
settings, birinapant treatment did not result in higher cell 
death intensity in M2 than in M1 macrophages at any dose. 
Ce
llT
ra
ck
er
-G
re
en
Propidium Iodide
M1-M2 M1-M2
Birinapant+Z-VAD
M1-M2
5Z-7+Z-VADA
B
D
ctr
l
5Z
-7 
+ Z
-V
AD
Bi
rin
ap
an
t +
 Z-
VA
D
0
20
40
60
80
%
 o
f c
el
l d
ea
th
M1
M2
*
CD
80
CD209
M1-M2 M1-M2
Birinapant+Z-VAD
M1-M2
5Z-7+Z-VAD
C
ctr
l
 5Z
-7 
+ Z
-V
AD
 B
irin
ap
an
t +
 Z-
VA
D
0
20
40
60
%
 o
f a
nt
ib
od
y 
po
si
tiv
e 
ce
lls CD80
CD209
*
Cancer Immunology, Immunotherapy 
1 3
Birinapant-induced cell death was even slightly, but nonsig-
nificantly, more intense in M1 cells (Fig. 2c). We checked 
whether the detected cell death in caspase-inhibited condi-
tions is due to necroptosis. For this, we pretreated the polar-
ized macrophages with a specific RIPK1 inhibitor Necrosta-
tin-1 (Nec-1) and RIPK3 inhibitor (GSKʹ872). We observed 
that Nec-1 and GSKʹ872 blocked birinapant/Z-VAD (BZ)-
induced cell death equally in the two cell types. In the case 
of M2 cells, Nec-1 and GSKʹ872 also inhibited the 5Z-7/Z-
VAD-induced cytotoxicity (Fig. 2d). We also analyzed the 
phosphorylation of MLKL following BZ and 5Z-7/Z-VAD 
activation as a characteristic marker of necroptosis. We 
detected phospho-MLKL upon BZ activation in both M1 
and M2 cells, but its phosphorylation occurred only in M2 
macrophages following 5Z-7/Z-VAD stimulation (Fig. 2e). 
TNF-R1: Fc fusion protein only partially, but not signifi-
cantly inhibited 5Z-7/Z-VAD or BZ -induced necroptosis, 
indicating that other mechanisms than autocrine TNF pro-
duction may also play a role in 5Z-7/Z-VAD- or BZ-induced 
necroptosis in human macrophages (data not shown).
Altogether, M2 macrophages are sensitive, but M1 cells 
are intrinsically resistant to 5Z-7/Z-VAD-induced necrop-
tosis, whereas all other examined stimuli caused the same 
intense cell death in the two differently polarized mac-
rophage populations.
Co‑culturing M1 and M2 cells does not sensitize M1 
cells to TAK1 inhibitor‑induced necroptosis
The two different macrophage phenotypes are present simul-
taneously at the site of chronic inflammation or in the tumor 
microenvironment. We tested the ability of the two cell 
types to regulate each other’s sensitivity to necroptosis by 
co-culturing M1 and M2 cells. We loaded M2 macrophages 
with CellTracker™ Green CMFDA Dye and co-cultured 
cells were treated with BZ or 5Z-7/Z-VAD for 24 h. We 
determined the intensity of cell death in both CellTracker-
positive and -negative populations. Consistent with the 
results observed with the separately treated cell types, M2 
cells were sensitive, but M1 cells remained resistant to 
5Z-7/Z-VAD-induced necroptosis. In contrast, BZ treatment 
effectively killed both macrophage populations in the co-
culture (Fig. 3a, b). We confirmed this result by measuring 
the cell surface markers of the surviving cell populations 
before and after the induction of cell death. 5Z-7/Z-VAD 
treatment reduced the amount of CD209 positive cells and 
consequently pushed the balance of M1/M2 cells toward M1 
excess, while BZ treatment had no significant effect on the 
M1/M2 ratio (Fig. 3c, d). Overall, the treatment of co-cul-
tured M1 and M2 macrophages with TAK1 inhibitor shifted 
the balance of surviving cells toward M1 dominance. Based 
on these results, we can conclude that the difference in the 
sensitivity of the two macrophage subtypes to necroptosis 
does not depend on M2-derived cytotoxic or M1-derived 
survival factors, but is regulated by the intrinsic properties 
of the two cell subtypes.
The inhibition of the downstream components 
of TAK1 signaling induces necroptosis in M2 cells
TAK1 regulates the activation of mitogen-activated protein 
kinases (MAPKs) and nuclear factor kappa B (NFkB) sign-
aling. We attempted to find which downstream component 
of TAK1 signaling could be responsible for TAK1 inhibitor-
induced necroptosis. For this purpose, molecules in TAK1-
regulated pathways were inhibited one by SP600125 (JNK 
inhibitor), SB203508 (p38MAPK inhibitor), U0126 (ERK 
inhibitor) and TPCA1 (IKK inhibitor). Under caspase-com-
promised conditions, all these inhibitors induced cell death 
in M2 macrophages. When we used suboptimal doses of 
these inhibitors, we detected more intense cell death in M2 
than in M1 cells. All observed differences were significant, 
except for p38 kinase inhibitors (Fig. 4a–d). Caspase activ-
ity protected both macrophage subtypes from MAPK or 
IKK inhibition-induced necroptosis. Combinations of these 
inhibitors also induced more intense cell death in M2 than in 
M1 macrophages (Fig. 4e). Phorbol 12-myristate 13-acetate 
(PMA) treatments resulted in comparable intense phospho-
rylation of MAPKs and IκB in M1 and M2 cells, indicat-
ing that the observed differences in cell death appear to be 
due to alterations in the necroptotic pathway, and not due to 
the availability of MAPK signaling (Figure Supplementary 
S1). According to our observations, we concluded that the 
absence of any survival signals results in the necroptosis of 
M2 cells under caspase-compromised conditions, but pre-
sumably M1 macrophages utilize additional survival signals 
to block TAK1 inhibition-mediated necroptosis.
Fig. 3  TAK1 inhibitor induces necroptosis on M2, but not on M1 
cells in the co-culture of macrophage populations. a, b M2 cells were 
loaded with 10 ng/ml CellTracker™ Green CMFDA Dye for 30 min. 
Green labeled M2 cells and M1 cells were mixed and the cells were 
treated with 0.5 μM birinapant or 1 μM 5Z-7-oxozeaenol with 50 μM 
Z-VAD. a The degree of total cell death was quantified based on the 
uptake of PI. b A representative image of five independent experi-
ments is documented. Percentage of cell death was calculated in the 
CellTracker positive and CellTracker negative populations. Figures 
show the mean plus SD of at least five independent experiments. c, 
d M1 and M2 cells were co-cultured and the cells were treated with 
0.5  μM birinapant or 1  μM 5Z-7-oxozeaenol in the presence of 
50 μM Z-VAD for 24 h. c The cell surface expression of CD80 and 
CD209 were measured by flow cytometry before and after 24 h the 
indicated treatments. The living cells were gated and the percentage 
of CD80 positive CD209 negative (CD80) and CD209-positive CD80 
negative (CD209) cells were determined. Figure shows the mean 
plus SD of at least five independent experiments. d The cell surface 
expression of CD80 and CD209 were measured by flow cytometry 
before or 24 h after the indicated treatments. A representative image 
of five independent experiments is shown
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Inhibitors of Aurora kinase A increased 
the sensitivity of M1 cells to TAK1 inhibitor‑induced 
necroptosis
To explore the molecular background behind the different 
sensitivities of M1 and M2 cells to necroptosis, we checked 
the protein expression of necrosome components in M1 and 
M2 cells. However, we could not detect considerable dif-
ferences in RIPK1, RIPK3 or MLKL expression (Fig. 5a). 
Because our results suggested the existence of an extra 
survival signal in M1 cells, we focused on the inhibitors 
of necroptosis. AURKA has been recently identified as 
an inhibitor of necroptosis, which binds to RIPK3 and/or 
RIPK1 in resting cells and blocks the assembly of the necro-
some [30]. GSK3β kinase was identified as the downstream 
mediator of AURKA in the downregulation of necropto-
sis. AURKA inhibitor (CCT137690) and GSK3β inhibitor 
(AR-A014418) have been shown to induce necroptosis in 
the PDAC cell line [30]. Our results show that treatment 
with CCT or AR had only minimal effect on macrophage 
survival under caspase-compromised conditions. Co-admin-
istration of BZ with these inhibitors did not significantly 
change the effect of BZ-induced necroptosis on either M1 
or M2 cells (Fig. 5d, e). Importantly, cell death of M1 cells 
was significantly higher upon 5Z-7/Z-VAD stimulus in the 
presence of either CCT or AR (Fig. 5b, c). To check the 
modality of cell death detected in the presence of CCT and 
AR, we pretreated the polarized macrophages with Nec-1 or 
GSKʹ872. We observed that Nec-1 and GSKʹ872 completely 
blocked the BZ-CCT- or BZ-AR-induced cell death (Fig. 5d, 
e, Figure Supplementary S2) and Nec-1 and GSKʹ872 also 
completely inhibited the 5Z-7/Z-VAD-CCT- or 5Z-7/Z-
VAD-AR-induced cell death in M1 and M2 cells (Fig. 5b, c, 
Figure Supplementary S2).
Because CCT or AR had no effect on 5Z-7/Z-VAD-
induced necroptosis on M2 cells, AURKA or GSK3β inhibi-
tors rendered the two macrophage populations equally sen-
sitive to TAK1 inhibitor-induced necroptosis. We checked 
the protein expression of AURKA and GSK3β in M1 and 
M2 cells, but could not detect any differences. These results 
indicate that the AURKA- or GSK3β-mediated survival 
pathway, but not the expression level of these kinases, may 
differ between M1 and M2 cells (Fig. 5a).
TAM‑like macrophages are sensitive 
to TAK1‑inhibitor‑induced necroptosis
Based on our observations (Fig. 2b), monocyte-derived M2 
cells are more prone to TAK1 inhibitor-induced necropto-
sis than M1 cells. Because the M2-like TAMs show simi-
lar functional properties to M2 macrophages, TAMs were 
in vitro differentiated and the cell death intensities of these 
TAM-like cells were compared to M1 cells (Fig. 6a–c). 
Isolated monocytes were plated in medium complemented 
with M-CSF and IL-10, IL-4 and TGFβ and the supernatant 
of THP-1 cells. In vitro differentiated TAM-like cells were 
characterized by flow cytometry. In good accordance with 
published data [34–36], these cells were CD206 and CD163 
positive, but expressed low amounts of CD14 (Fig. 6b, c), 
while the appearance of MCHII [37] and PD-1 [38] was 
more intense on the surface of TAM-like cells compared to 
M1 and M2 macrophages (Fig. 6c). The differentiated TAM-
like cells were treated with BZ and 5Z-7/Z-VAD to induce 
necroptosis. We found that TAM-like cells were as sensi-
tive to BZ-induced necroptosis as M1 cells, but significantly 
more susceptible to 5Z-7/Z-VAD treatments than M1 mac-
rophages (Fig. 6d). Sensitivity of TAM-like macrophages 
to TAK1-inhibitor-induced necroptosis promises to be an 
effective therapeutic strategy to eliminate immunosuppres-
sive macrophages, while preserving the inflammatory M1 
cells in the tumor microenvironment.
Discussion
Due to the heterogenicity of macrophages, dramatic func-
tional differences have been observed depending on their 
polarization. The two extremes in the spectrum are M1 
macrophages, which are responsible for the initiation of 
inflammation, and alternatively activated M2 macrophages 
with anti-inflammatory properties. Targeted modulation of 
M1/M2 transition may offer promising strategies to cure 
various life-threatening diseases. Accordingly, ongoing 
clinical trials aim to modulate M1/M2 balance in cancer 
[5, 6], atherosclerosis [2], sclerosis multiplex [39] or endo-
metriosis [40]. Currently, the therapeutic approaches to 
alter the ratio of macrophage subsets are bipartite, on the 
one hand directing the differentiation of these cells, and 
on the other hand, altering the function of the differenti-
ated cells [6]. In addition, targeted depletion of each mac-
rophage type also offers a therapeutic option to regulate 
the M1/M2 ratio. This strategy can be relevant, especially 
in TME, where cell death induction is certainly the main 
therapeutic intervention [6]. Necroptotic stimuli, among 
them SMs [41] and TAK1 inhibitors [42], have been tested 
in various ongoing clinical trials to eliminate apoptosis-
resistant tumor cells. However, necroptosis induction in 
Fig. 4  p38MAPK, JNK, ERK and IKK inhibitors induce cell death in 
M2 macrophages. The in vitro differentiated human M1 and M2 cells 
were stimulated in the presence or absence of 50 μM Z-VAD for 24 h 
with the indicated dose of a SP600125 (JNK inhibitor), b SB203508 
(p38MAPK inhibitor), c U0126 (ERK inhibitor) and d TPCA1 (IKK 
inhibitor) or e with the combinations of these inhibitors. The degree 
of total cell death was quantified based on the uptake of PI. Figures 
show the mean plus SD of at least five independent experiments. # 
represents significant differences to the Z-VAD treated sample
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the TME is a double-edged sword, because necroptosis 
in the TME can also result in immunosuppression, and 
necroptotic cell death of endothelial cells promotes tumor 
cell extravasation and  metastasis [18]. Consequently, 
the effect of any necroptosis inducers should be checked 
also on the TME in addition to its tumor-killing capac-
ity. The effect of SM and TAK1 inhibitors on the cellu-
lar components of tumor-associated stroma is not clearly 
investigated.
Macrophages are relatively resistant to apoptosis, but 
are highly sensitive to necroptosis [43]. SMAC mimetics 
have been reported to trigger cell death in macrophages, 
especially under caspase-compromised conditions [31], and 
TAK1 inhibitors are also well known to induce necroptosis 
in macrophages [14].
We attempted to compare the sensitivity of M1 and M2 
macrophages to various cell death stimuli. The two mac-
rophage populations were equally sensitive to most of the 
investigated apoptotic or necroptotic inductions, but we 
observed that monocyte-derived M2 cells are more prone to 
TAK1 inhibitor-induced necroptosis than M1 cells. Because 
the M2-like TAMs generally show similar functional proper-
ties as M2 macrophages, the question arose as to whether 
these two anti-inflammatory populations use similar cell 
death pathways. We generated TAM-like cells in vitro by 
using the traditional M2 differentiation protocol and THP-1 
conditioned media. TAM-like macrophages, as well as M2 
cells, were sensitive to TAK1 inhibitor-induced necroptotic 
stimuli. The difference in the sensitivity of M1 and M2 mac-
rophages to TAK1 inhibitor-induced necroptosis was still 
observed when the two cell populations were co-cultured, 
which results in exclusion the possibility that the effect is 
due to an autocrine cytotoxic factor exclusively produced 
by M2 cells. Our findings suggest that TAK1 inhibitors are 
more promising candidates for tumor therapy than SM due 
to the intense killing of anti-inflammatory macrophages. 
However, further investigations are needed to check the 
effect of the two necroptotic treatments on other suppres-
sive cell types in the TME, and in vivo studies should also 
be performed to investigate the recruitment of various cells 
following treatments with both TAK1 inhibitor and SM. The 
use of TAK1 inhibitor instead of SM is rationalized not only 
by the susceptibility of M2- and TAM-like macrophages to 
TAK1 inhibitor-induced necroptosis but also by the fact 
that TAK1-mediated events also have been demonstrated in 
all growth factor signaling, Treg cell development, epithe-
lial–mesenchymal transition, angiogenesis and in resistance 
to conventional chemotherapy [42].
Investigation of the intrinsic signaling pathways of the 
two cell types indicates that any perturbation in the survival 
signals resulted in necroptosis in M2 cells, but M1 cells 
were relatively unaffected. The higher degree of resistance 
indicates the existence of a special survival signal in M1 
cells. AURKA acts as a local inhibitor against spontaneous 
necroptosis, by associating with RIPK3 and RIPK1 in rest-
ing cells [30]. In the presence of AURKA inhibitors, M1 
cells became as sensitive to TAK1 inhibitor-induced cell 
death as the M2 cells were. GSK3β was identified as the 
downstream target of AURKA in the regulation of necrop-
tosis [30], and consequently, GSK3β inhibitors also restored 
the sensitivity of M1 cells to TAK1 inhibitor-induced cell 
death. AURKA inhibitors are also intensively studied in 
tumor therapy [44], but their effect on TME is less inten-
sively investigated. Hereby, we highlight that AURKA may 
have an effect on the immunosuppressive microenvironment, 
keeping M1 cells alive, which can be considered in thera-
peutic approaches using AURKA inhibitors either alone or 
in co-therapy.
More than 20 drugs, approved mostly in cancer therapy, 
but also in autoimmune or neurodegenerative disorders, 
have the potential to regulate necroptosis [18]. How these 
drugs modify the life span of M1/M2 cells still have not 
been investigated, but this effect may have influence on the 
current applications of necroptosis regulators.
Two different types of necroptosis have been detected by 
TNF induction in 661 W mouse photoreceptor cell lines. 
Activation of TNF/5Z-7/Z-VAD resulted in different necrop-
tosis than TNF/CHX/Z-VAD concerning the molecular 
composition and also the signal transduction of necroptotic 
pathway [45].
Our results indicate heterogeneous functionality of dif-
ferent necroptotic stimuli, highlighting the importance of 
specifying and differentiating necroptotic pathways. Overall, 
our findings provide new approaches to regulate the balance 
of M1/M2 cells in the treatment for various diseases such as 
cancer or chronic infections.
Fig. 5  Aurora kinase A inhibitor restores the TAK1 inhibitor-induced 
cell death in M1 macrophages. a The expressions of the indicated 
molecules were visualized by western blotting of total cell lysates in 
the in vitro differentiated human M1 and M2 cells. A representative 
image of three independent experiments is documented. b, c Mac-
rophages were pre-treated with 1.25 μM CCT137690 (AURKA inhib-
itor) and 10 μM AR-A014418 (GSK3β) inhibitor, 38.5 μM Necrosta-
tin-1 for 1  h followed by activation with 1  μM 5Z-7-oxozeaenol 
together with 50 μM Z-VAD. d, e Macrophages were pre-treated with 
1.25  μM CCT137690 (AURKA inhibitor) and 10  μM AR-A014418 
(GSK3β) inhibitor, 38.5 μM Necrostatin-1 for 1 h followed by activa-
tion with 0.5 μM birinapant together with 50 μM Z-VAD. b–e After 
24  h the extent of cell death was determined by measuring the PI 
staining. The figure shows the mean plus SD of at least five independ-
ent experiment
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